Description

Overview

CJC-1295 and Ipamorelin are both considered growth hormone secretagogues. Ipamorelin is a synthetic pentapeptide, while CJC-1295 is a 29 amino acid peptide derived from growth hormone-releasing hormone (GHRH). Ipamorelin acts on ghrelin receptors (GHS-R1a), stimulating GH release selectively, whereas CJC-1295 mimics GHRH to stimulate GH secretion from somatotroph cells in the anterior pituitary. Their differing pharmacokinetic profiles make them complementary: Ipamorelin acts quickly, while CJC-1295 sustains GH elevation for longer periods.

Chemical Makeup

• CJC-1295: C152H252N44O42 – 3367.9 g/mol
• Ipamorelin: C38H49N9O5 – 711.8 g/mol
• Other Known Titles: • CJC-1295 – Mod GRF (1-29), CJC-1295 No DAC • Ipamorelin – NNC 26-0161

Mechanism of Action

CJC-1295 binds to GHRH receptors, triggering G-protein signaling cascades that increase cAMP and activate protein kinases, leading to GH gene transcription and secretion. Ipamorelin binds to ghrelin receptors (GHS-R1a), activating Gαq/11 proteins and phospholipase C (PLC). This splits PIP2 into IP3 and DAG, leading to calcium release and PKC activation, ultimately stimulating GH secretion. Together, they synergistically trigger GH release from different receptor pathways.

Pharmacokinetics and Half-Life

Ipamorelin exhibits a short half-life of approximately 2 hours, with GH release peaking around 0.67 hours after presentation. CJC-1295 demonstrates a significantly longer half-life of 5.8–8.1 days, sustaining GH and IGF-1 elevation. When combined, Ipamorelin initiates rapid GH release, while CJC-1295 maintains elevated levels over time, providing a layered effect on GH pulsatility.

Research Findings

Clinical studies in the early 2000s observed a 7.5-fold increase in GH pulsatility with CJC-1295 exposure. It also upregulated IGF-1 levels by 45% on average. Animal studies indicated increased pituitary RNA and GH mRNA, suggesting somatotroph proliferation. Ipamorelin’s metabolic effects have been linked to improved nitrogen balance, with observed reductions in hepatic urea-N production and modulation of urea cycle enzymes. Together, the blend may support lean mass preservation, GH optimization, and anabolic balance.

Disclaimer

All products offered by America1stPeptides.com are intended strictly for laboratory and scientific research purposes only. These products are not approved by the FDA, are not medicines or supplements, and are not sold for human consumption, medical treatment, or veterinary use. Any discussion of potential benefits is based solely on preclinical findings.